Robert W. Baird Issues Pessimistic Forecast for Sarepta Therapeutics (NASDAQ:SRPT) Stock Price

Sarepta Therapeutics (NASDAQ:SRPT) had its target price lowered by Robert W. Baird from $200.00 to $193.00 in a research note published on Thursday morning,Benzinga reports. Robert W. Baird currently has an outperform rating on the biotechnology company’s stock.

Other analysts also recently issued reports about the stock. UBS Group increased their price target on shares of Sarepta Therapeutics from $173.00 to $188.00 and gave the company a “buy” rating in a research report on Tuesday, September 17th. Raymond James reiterated an “outperform” rating and issued a $150.00 target price on shares of Sarepta Therapeutics in a report on Thursday, October 10th. Evercore ISI lowered their price objective on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating for the company in a research report on Thursday. Needham & Company LLC reiterated a “buy” rating and set a $205.00 target price on shares of Sarepta Therapeutics in a report on Thursday. Finally, Citigroup decreased their target price on Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating for the company in a research note on Thursday, August 8th. One research analyst has rated the stock with a hold rating, twenty have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $181.33.

Sarepta Therapeutics Trading Up 1.0 %

Shares of SRPT traded up $1.19 during trading hours on Thursday, hitting $121.61. 1,483,804 shares of the stock traded hands, compared to its average volume of 1,234,525. The business has a fifty day moving average of $126.20 and a 200-day moving average of $132.77. The firm has a market capitalization of $11.60 billion, a PE ratio of 97.29 and a beta of 0.81. Sarepta Therapeutics has a 1-year low of $75.85 and a 1-year high of $173.25. The company has a current ratio of 3.90, a quick ratio of 3.19 and a debt-to-equity ratio of 1.05.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of $0.01 by $0.06. Sarepta Therapeutics had a return on equity of 5.32% and a net margin of 3.14%. The business had revenue of $362.90 million during the quarter, compared to analysts’ expectations of $394.38 million. During the same period in the previous year, the firm earned ($0.27) earnings per share. The firm’s quarterly revenue was up 38.9% compared to the same quarter last year. Analysts expect that Sarepta Therapeutics will post 1.48 EPS for the current year.

Insider Activity at Sarepta Therapeutics

In other news, Director Michael Andrew Chambers bought 37,038 shares of the stock in a transaction that occurred on Friday, August 16th. The shares were acquired at an average cost of $133.80 per share, for a total transaction of $4,955,684.40. Following the completion of the acquisition, the director now owns 284,034 shares in the company, valued at approximately $38,003,749.20. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Sarepta Therapeutics news, Director Michael Andrew Chambers purchased 37,038 shares of Sarepta Therapeutics stock in a transaction that occurred on Friday, August 16th. The stock was acquired at an average price of $133.80 per share, for a total transaction of $4,955,684.40. Following the completion of the acquisition, the director now owns 284,034 shares of the company’s stock, valued at approximately $38,003,749.20. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Ian Michael Estepan sold 5,985 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the sale, the chief financial officer now owns 33,946 shares in the company, valued at $4,662,822.56. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 7.70% of the company’s stock.

Hedge Funds Weigh In On Sarepta Therapeutics

Large investors have recently modified their holdings of the stock. Farallon Capital Management LLC raised its holdings in Sarepta Therapeutics by 102.8% in the 1st quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock valued at $317,630,000 after acquiring an additional 1,243,427 shares during the period. Principal Financial Group Inc. boosted its stake in Sarepta Therapeutics by 693.7% in the 2nd quarter. Principal Financial Group Inc. now owns 363,011 shares of the biotechnology company’s stock valued at $57,356,000 after purchasing an additional 317,277 shares during the period. Canada Pension Plan Investment Board grew its holdings in Sarepta Therapeutics by 2,257.8% in the 1st quarter. Canada Pension Plan Investment Board now owns 240,500 shares of the biotechnology company’s stock valued at $31,135,000 after buying an additional 230,300 shares in the last quarter. Rhumbline Advisers increased its position in Sarepta Therapeutics by 146.3% during the 2nd quarter. Rhumbline Advisers now owns 270,941 shares of the biotechnology company’s stock worth $42,809,000 after buying an additional 160,942 shares during the period. Finally, Blair William & Co. IL lifted its holdings in shares of Sarepta Therapeutics by 303.7% during the second quarter. Blair William & Co. IL now owns 174,282 shares of the biotechnology company’s stock worth $27,537,000 after buying an additional 131,112 shares in the last quarter. 86.68% of the stock is owned by institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.